UBXN11 and chronic kidney disease: A subgroup analysis of the overall population aged >55 years and in CKD stages G3 or G4 using the piecewise mixed model yielded an annual rate of eGFR decline of −2.40 mL/min/1.73 m2 for tolvaptan and −3.33 mL/min/1.73 m2 for SOC, with a significant difference of 0.93 mL/min/1.73 m2 (95% CI, 0.28-1.58; P = 0.005).